Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The Anti-Obesity Medications market is expanding rapidly, becoming a major influence in the food industry Strong demand signals suggest sustained growth for Anti-Obesity Medications Anti-Obesity ...

A commercial airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs ...

The ad emphasizes the role of the food and health system in the obesity epidemic and fails to include any specific information about the potential risks and side effects of Hims’ drugs being ...

Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while ...